Abstract Number: 2686 • ACR Convergence 2025
Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Background/Purpose: RA and PsA follow different pathomechanisms and incur disease-specific erosive and osteoproliferative bone changes. We used data from a large cohort of RA and…Abstract Number: 2363 • ACR Convergence 2025
Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), yet the comparative safety of…Abstract Number: 2323 • ACR Convergence 2025
Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic rheumatic disease that develops in up to one-third of patients with psoriasis. Identifying predictive factors for PsA in…Abstract Number: 1945 • ACR Convergence 2025
Significance of Finger Joint Tenderness With or Without Swelling in Relation to MRI, Ultrasound, and X-Ray Findings in Psoriatic Arthritis_Final results
Background/Purpose: Musculoskeletal involvement in psoriatic arthritis (PsA) affects both articular and extra-articular structures, presenting as inflammatory and structural lesions. The relationship between tender and/or swollen…Abstract Number: 1460 • ACR Convergence 2025
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…Abstract Number: 1427 • ACR Convergence 2025
Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk due to a higher prevalence of comorbidities and chronic systemic inflammation. In those…Abstract Number: 1098 • ACR Convergence 2025
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Background/Purpose: Apremilast, a PDE-4 inhibitor, is commonly indicated for patients with psoriasis as well as Behçet’s disease. Although this medication is generally well tolerated, numerous…Abstract Number: 0570 • ACR Convergence 2025
Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Background/Purpose: A substantial number of patients with rheumatic inflammatory/autoimmune diseases, do not achieve adequate symptom control with current standard-of-care therapies, including biologics. The endocannabinoid system…Abstract Number: 0831 • ACR Convergence 2025
Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis
Background/Purpose: Preclinical phases of rheumatoid arthritis (RA), including therapeutic interventions, have been extensively studied. There is a growing focus on individuals at risk for psoriatic…Abstract Number: 0455 • ACR Convergence 2025
Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis
Background/Purpose: Patients rate pain as one of the most important aspects of psoriatic arthritis (PsA). Pain signaling involves a series of cytokines, including those downstream…Abstract Number: 0586 • ACR Convergence 2025
Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
Background/Purpose: Check point inhibitor PD-1 (programmed death protein 1) is upregulated during T lymphocyte activation and is important for limiting the duration of activation. Thus,…Abstract Number: 2613 • ACR Convergence 2025
Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis
Background/Purpose: 68Ga-FAPI-04 PET/CT reveals fibroblast activation in vivo and is increasingly used to assess rheumatic diseases, including inflammatory arthritides. (1,2) We previously demonstrated that the…Abstract Number: 2362 • ACR Convergence 2025
Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Background/Purpose: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, is approved for the treatment of adults with active PsA. We report the efficacy and safety of…Abstract Number: 2321 • ACR Convergence 2025
Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis
Background/Purpose: Spondyloarthritis (SpA) impacts patient’s life, including functionality, QoL, emotional state, and sexual function. The current study was conducted to determine the frequency of sexual…Abstract Number: 1911 • ACR Convergence 2025
Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort
Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 93
- Next Page »